On December 22, 2025, ABBISKO-B (02256) announced that its subsidiary, Shanghai ABBISK Biopharmaceutical Co., Ltd. ("ABBISK Medicine"), received approval from China's National Medical Products Administration (NMPA) for Beijiemai® (pimicotinib hydrochloride capsules). The drug is indicated for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) where surgical resection may lead to functional limitations or severe complications. Following approval, Merck will expedite efforts to make the treatment available to TGCT patients in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments